ArticleFrontiers in oncology2026
Venetoclax combined with azacitidine in the treatment of secondary myelodysplastic syndrome following multiple myeloma: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a retrospective analysis of the clinical data of a patient with myelodysplastic syndrome (MDS) secondary to stable multiple myeloma (MM), who was treated with a combination of venetoclax and azacitidine at the Fifth People's Hospital of Chengdu. Additionally, we reviewed the relevant literature. The patient, a 74-year-old male, was initially diagnosed with multiple myeloma (IgA-γ, DS IIIA, ISS III, R-ISS II) and achieved a very good partial response (VGPR) following sequential treatments with BCTD, RVD, and PVD regimens, subsequently receiving maintenance therapy with pomalidomide. Despite being in continuous remission, the patient developed secondary myelodysplastic syndrome characterized by refractory anemia with excess blasts-2 (MDS-RAEB-II) 51 months post-initial MM diagnosis. He was then treated with venetoclax in combination with azacitidine. After the first treatment course, the patient achieved morphological partial remission of MDS. However, due to non-adherence to continuous treatment, he ultimately succumbed to a secondary infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.